CYTOTEC Drug Patent Profile

« Back to Dashboard

Which patents cover Cytotec, and when can generic versions of Cytotec launch?

Cytotec is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in CYTOTEC is misoprostol. Sixteen suppliers are listed for this compound. Additional details are available on the misoprostol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cytotec

A generic version of CYTOTEC was approved as misoprostol by ANI PHARMS on July 10^th, 2002.

Summary for CYTOTEC

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CYTOTEC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	CYTOTEC	misoprostol	TABLET;ORAL	019268-003	Sep 21, 1990	AB	RX	Yes	No
Pfizer	CYTOTEC	misoprostol	TABLET;ORAL	019268-001	Dec 27, 1988	AB	RX	Yes	Yes

International Patents for CYTOTEC

See the table below for patents covering CYTOTEC around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	207355	UN PROCEDIMIENTO PARA LA PREPARACION DE DERIVADOS DEL ACIDO 7-(-(4-HIDROXI-4-ALQUIL-1-ALQUENIL)CICLOPENTANO)-1-HEPTANOICO
Austria	351684
Austria	A227375
Australia	7947175
Belgium	827127
Canada	1040197	DERIVES D'ACIDE PROSTANOIQUE OXYGENE EN 16 (16-OXYGENATED PROSTANOIC ACID DERIVATIVES)
Switzerland	613443

Investment Scenario and Fundamentals Analysis for CYTOTEC (Misoprostol)

Last updated: February 25, 2026

What is CYTOTEC?

CYTOTEC is the commercial name for misoprostol, a prostaglandin E1 analog. It is primarily used for the prevention and treatment of gastric ulcers caused by NSAIDs, as well as for induction of labor and medical termination of pregnancy in certain markets. The drug has a well-established manufacturing process and regulatory track record, with extensive off-label uses.

Market Overview

Global Market Size

The global misoprostol market, including CYTOTEC and generics, was valued at approximately USD 280 million in 2022. The compound annual growth rate (CAGR) from 2023 to 2028 is estimated at 4.2%, driven by expanding indications and increasing access in emerging markets.

Therapeutic Area Trends

• Gastrointestinal use: Remains the primary application, but growth is steady due to NSAID-induced ulcer management.
• Reproductive health: Significant growth potential exists, especially in regions with limited access to surgical termination procedures.
• Off-label uses: Include treatment of postpartum hemorrhage, which has garnered WHO recommendation, boosting demand in low-to-middle income countries.

Key Market Players

• Pfizer (original patent holder)
• Indian generics manufacturers (e.g., Zydus, Cipla)
• Chinese companies with local manufacturing and supply rights

Note: The original patent for misoprostol expired in the early 2000s, leading to a broad generic presence.

Regulatory and Patent Landscape

Patent Status

CYTOTEC's patent expired in 2002 globally. Patent protections for proprietary formulations are no longer in effect, enabling generic competition.

Regulatory Approvals

CYTOTEC has approval from major agencies:

• US FDA: Approved for gastric ulcers and induction of labor.
• EMA: Approved for similar indications.
• WHO: Recognizes misoprostol for postpartum hemorrhage management.

Regulatory barriers mainly involve country-specific registration, especially for reproductive health uses.

Regulatory Risks

• Restrictions on reproductive uses in some regions.
• Variability in regulatory clarity for off-label applications.

Commercial and Investment Risks

Pricing Pressure

Generics dominate the market, causing price erosion. The average wholesale price in the US dropped from USD 1.50 per tablet in 2010 to below USD 0.50 in 2022.

Supply Chain and Manufacturing Risks

High-volume manufacturing is feasible due to the established synthesis process. However, supply risks exist in regions with less developed infrastructure.

Market Access and Accessibility

Demand is increasing in low- to middle-income countries. Implementation of WHO guidelines enhances access, especially for postpartum hemorrhage treatments.

Competitive Landscape

The market is saturated with generics. Differentiation depends on price, supply reliability, and regional registration strategies.

Financial Fundamentals

Revenue and Profitability

• Market Revenue (2022): USD 280 million globally.
• Growth Drivers: Expansion in reproductive health indications, government procurement programs, WHO recommendations.
• Profit Margins: Due to high generic competition, gross margins are typically 15–20%.

Cost Structure

Manufacturing costs are low, estimated at around USD 0.05–0.10 per tablet. Regulatory and marketing costs vary by region.

Investment in R&D

Minimal, as the drug is off-patent with established manufacturing procedures. Focus is on distribution and regulatory approval expansion.

Future Outlook and Strategic Recommendations

Opportunities

• Expand registration in Africa and Southeast Asia for postpartum hemorrhage.
• Develop combination formulations to improve use compliance.
• Partner with NGOs for bulk procurement in underserved regions.

Challenges

• Regulatory hurdles in certain jurisdictions.
• Market saturation with low-cost generics.
• Sensitivity around reproductive health indications.

Investment Impact

Potential for moderate revenue growth, primarily through geographic expansion and off-label indications. Considering market saturation, profit margins are under pressure, and any new product development is unlikely.

Key Financial Metrics Summary

Metric	Value/Estimate	Notes
Global market size (2022)	USD 280 million	Including generics
CAGR (2023–2028)	4.2%	Driven by emerging markets and indications
Average price per tablet	USD 0.50	Declining trend
Gross margins	15–20%	Due to intense generic competition
Regulatory approval count	80+ countries	Varies by application

Key Takeaways

• CYTOTEC is a low-cost, off-patent product with a stable market base.
• Growth stems from increasing use in reproductive health and postpartum hemorrhage management, especially in emerging markets.
• Competition from generics keeps prices under pressure; operating margins are modest.
• Market expansion depends heavily on regulatory approval and government procurement strategies.
• Limited innovation opportunities suggest that future revenue depends on geographic and indication expansion rather than new formulations.

FAQs

1. What are the main commercial risks for investing in CYTOTEC?
Market saturation with low-cost generics diminishes profit margins. Regulatory restrictions, especially around reproductive indications, pose additional risks.

2. How does the expiration of patents affect market competition?
Patent expiry in 2002 permitted broad generic manufacturing, intensifying price competition but reducing barriers to market entry.

3. What are key regional growth opportunities?
Expanding registration and use in Africa, Southeast Asia, and Latin America, especially for postpartum hemorrhage treatment.

4. Are there significant R&D costs for CYTOTEC?
No. The drug is off-patent with well-established manufacturing processes; focus primarily on distribution and regulatory approval.

5. How does WHO’s endorsement influence market dynamics?
It facilitates procurement in low-income countries, expanding demand in the reproductive health sector.

---

References

[1] MarketWatch. (2023). Global misoprostol market report.
[2] WHO. (2020). Guidelines for the management of postpartum hemorrhage.
[3] U.S. Food and Drug Administration. (2022). CYTOTEC approval details.
[4] Grand View Research. (2023). Generic drugs market analysis.
[5] IMS Health. (2022). Pharmaceutical price trends.